Alternate cancer treatments are more expensive

Cisplatin, an essential cancer drug, faced severe global shortages in 2023. Scientists analyzed the cost difference between platinum-based drug containing regimens and the recommended alternative regimens for head and neck, small cell lung, and urothelial cancers, and found that the average cost increase when substituting alternative regimens was $46,943 per patient across tumor types.